BioCardia, Inc. (NASDAQ:BCDA) Short Interest Down 49.4% in April

BioCardia, Inc. (NASDAQ:BCDA) saw a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 271,200 shares, a decrease of 49.4% from the March 31st total of 535,900 shares. Based on an average trading volume of 345,100 shares, the short-interest ratio is currently 0.8 days.

BioCardia Stock Performance

Shares of NASDAQ BCDA traded up $0.01 during mid-day trading on Friday, reaching $0.38. The company’s stock had a trading volume of 20,244 shares, compared to its average volume of 317,581. The stock has a 50-day moving average of $0.41 and a two-hundred day moving average of $0.50. The stock has a market capitalization of $10.12 million, a P/E ratio of -0.67 and a beta of 1.47. BioCardia has a 1-year low of $0.32 and a 1-year high of $2.92.

BioCardia (NASDAQ:BCDA) last announced its quarterly earnings data on Wednesday, March 27th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. BioCardia had a negative net margin of 2,425.79% and a negative return on equity of 3,638.68%. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.20 million. Analysts predict that BioCardia will post -0.42 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Peter Altman acquired 108,108 shares of BioCardia stock in a transaction on Tuesday, February 13th. The stock was bought at an average cost of $0.46 per share, for a total transaction of $49,729.68. Following the completion of the transaction, the chief executive officer now owns 555,447 shares of the company’s stock, valued at approximately $255,505.62. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders purchased 111,358 shares of company stock worth $50,942. Company insiders own 23.90% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in BioCardia stock. CM Management LLC boosted its stake in shares of BioCardia, Inc. (NASDAQ:BCDA) by 74.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 600,000 shares of the company’s stock after buying an additional 257,000 shares during the quarter. CM Management LLC owned 2.78% of BioCardia worth $258,000 as of its most recent SEC filing. Institutional investors own 20.57% of the company’s stock.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease.